Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02901067 · ClinicalTrials.gov registry record · Phase 2
STAT-STatin and Aspirin in Trauma
A Phase 2 study, sponsored by Denver Health and Hospital Authority.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02901067: Clinical Trial Phase 2 study, sponsored by Denver Health and Hospital Authority.
NCT02901067 is a Phase 2 study that was terminated before completion, run by Denver Health and Hospital Authority. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02901067, a Phase 2 study, was terminated before completion, sponsored by Denver Health and Hospital Authority.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a phase II, pragmatic, prospective, randomized, double-blind, adaptive clinical trial examining the efficacy of statins and aspirin in the reduction of acute lung injury and venous thromboembolism in patients with fibrinolysis shutdown.
Primary Outcome
Based on screening duplex ultrasound (US) of legs and central line on day 5 or upon ICU discharge or upon symptoms of VTE (whichever comes first).
Interventions
- DRUG Aspirin and Rosuvastatin
- DRUG Placebo (for Aspirin and Rosuvastatin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2021-08-01 |
| Phase | Phase 2 |
Why NCT02901067 stopped before completion
NCT02901067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Aspirin and Rosuvastatin is the first listed.
NCT02901067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02901067 about?
NCT02901067 is a clinical study titled "STAT-STatin and Aspirin in Trauma". This is a phase II, pragmatic, prospective, randomized, double-blind, adaptive clinical trial examining the efficacy of statins and aspirin in the reduction of acute lung injury and venous thromboembolism in patients with fibrinolysis shutdown.
What is the current status of trial NCT02901067?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2017-02-03. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT02901067?
The interventions under investigation include: Aspirin and Rosuvastatin (DRUG), Placebo (for Aspirin and Rosuvastatin) (DRUG).
Who is sponsoring clinical trial NCT02901067?
This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02901067's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI